Munich University Clinic, Ludwig-Maximilians-University and German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany.
Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Can J Cardiol. 2019 Feb;35(2):199-207. doi: 10.1016/j.cjca.2018.11.035. Epub 2018 Dec 12.
Several clinical and procedural factors determine outcomes after transcatheter aortic valve replacement (TAVR), but data are scarce on the impact of post-TAVR discharge disposition on long-term outcomes. We sought to analyse whether discharge location after TAVR is associated with 1-year outcomes in women undergoing contemporary TAVR.
The Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) registry is the first all-female TAVR registry to study the safety and performance of contemporary TAVR in women (n = 1019). Information on discharge location was available in 817 patients (80.2%). We compared women discharged home vs those discharged to another location (nursing home, rehabilitation, or other hospital). One-year outcomes were adjusted using multivariable Cox regression methods with discharge home as the reference group.
Of the study subjects, 75.2% (n = 614) were discharged home and 24.8% (n = 203) to another location. Women discharged to other locations were older with a greater prevalence of severe lung disease requiring home oxygen and renal failure on dialysis but were less frequently considered frail or at high surgical risk compared with women discharged home. After multivariable adjustment, non-home discharge was associated with greater hazard for 1-year Valve Academic Research Consortium 2 efficacy (21.3% vs 10.8%, hazards ratio [HR] 1.9, 95% confidence interval [CI] 1.2-2.9) and safety endpoints (31.5% vs 15.2%, HR 2.1, 95% CI 1.5-3.0), cardiovascular death (12.7% vs 5.5%, HR 2.0, 95% CI 1.1-3.6), and stroke (6.5% vs 0.8%, HR 8.5, 95% CI 2.9-25.6).
In women undergoing contemporary TAVR, discharge disposition significantly affects 1-year risk of outcomes even after adjustment for recorded baseline differences. This might suggest the necessity of considering additional factors beyond comorbidities in the TAVR decision-making process.
经导管主动脉瓣置换术(TAVR)后的几个临床和程序因素决定了结果,但关于 TAVR 后出院去向对长期结果的影响的数据很少。我们旨在分析女性行当代 TAVR 后出院地点是否与 1 年结局相关。
女性国际经导管主动脉瓣植入术(WIN-TAVI)登记处是首个研究当代 TAVR 在女性中的安全性和表现的全女性 TAVR 登记处(n=1019)。有 817 例患者(80.2%)可获得出院地点信息。我们将出院回家的患者与出院到其他地方(疗养院、康复医院或其他医院)的患者进行了比较。使用多变量 Cox 回归方法,以出院回家为参考组,调整 1 年结局。
在研究对象中,75.2%(n=614)出院回家,24.8%(n=203)出院到其他地方。出院到其他地方的女性年龄较大,更常患有需要家庭吸氧的严重肺部疾病和需要透析的肾功能衰竭,但与出院回家的女性相比,她们被认为虚弱或手术风险较高的比例较低。经多变量调整后,非家庭出院与 1 年 Valve Academic Research Consortium 2 疗效(21.3%比 10.8%,危险比[HR]1.9,95%置信区间[CI]1.2-2.9)和安全性终点(31.5%比 15.2%,HR 2.1,95% CI 1.5-3.0)、心血管死亡(12.7%比 5.5%,HR 2.0,95% CI 1.1-3.6)和卒中(6.5%比 0.8%,HR 8.5,95% CI 2.9-25.6)的风险显著增加。
在接受当代 TAVR 的女性中,即使在调整记录的基线差异后,出院去向仍显著影响 1 年结局风险。这可能表明,在 TAVR 决策过程中,除了合并症之外,还需要考虑其他因素。